Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

turing_pharma

Turing will drop price of Daraprim following outrage

September 24, 2015 Sales and Marketing Daraprim, Impax Laboratories, Martin Shkreli, Turing Pharmaceuticals, toxoplasmosis

Martin Shkreli, whose company Turing Pharmaceuticals increased the price of Daraprim more than fifty-fold overnight, has been forced to backpedal …
News
martin_shkreli

Anger as drug price rises from $13.50 to $750 overnight

September 22, 2015 Manufacturing and Production, Sales and Marketing pyrimethamine, turing

Turing founder Martin Shkreli has been forced to defend the company’s decision to raise the price of the drug Daraprim …
News

Featured market report: Cancer diagnostics market – Forecast to 2020

September 22, 2015 Manufacturing and Production, Sales and Marketing cancer diagnostics, market report, marketsandmarkets

The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms.Moreover, the market …
Feature
Shire

Shire ADHD treatment Intuniv gets EU approval

September 21, 2015 Sales and Marketing ADHD, Shire, attention deficit hyperactivity disorder, intuniv

The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children.  Intuniv (guanfacine hydrochloride prolonged …
News
Klaus Henning Jensen

Working Life: Novo Nordisk’s Klaus Henning-Jensen

September 21, 2015 Sales and Marketing Novo Nordisk, Working Life

How did you find your way into your current role?I started out in medicine at Bispebjerg, which is a large …
Feature
Amgen image

Amgen’s Kyprolis gets accelerated FDA review for expanded labelling

September 21, 2015 Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma

The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …
News
Esbriet

Roche to present new Esbriet data at ERS Congress 2015

September 21, 2015 Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone

Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …
News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015 Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …
News

Biocair opens new site in Belgium

September 21, 2015 Research and Development, Sales and Marketing Biocair

Biocair is pleased to announce the opening of its new premises in Belgium. The new state of the art facility …
News
Press release

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015 Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
News
eugene_van_rensburg-astellas

Astellas Pharma EMEA appoints new chief financial officer

September 17, 2015 Sales and Marketing Astellas, Eugene Van Rensburg

Astellas Pharma Europe, Middle East and Africa has appointed Eugene Van Rensburg to the position of chief financial officer, from …
Appointment
Abraxane

NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’

September 17, 2015 Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer

NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
News
ABPI

PMPCA rules on multiple pharma code breaches

September 17, 2015 Medical Communications, Sales and Marketing ABPI, ABPI Code, PMCPA, Prescriptions Medicine Code of Practice Authority

The industry’s code of conduct regulator has ruled on several alleged breaches of the ABPI code of pharmaceutical conduct by …
News
Amgen

Amgen joins M&A rush with deals for Dezima and Xencor

September 16, 2015 Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation

Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
News
Farydak

NICE rejects Farydak for multiple myeloma

September 16, 2015 Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026